Trial Profile
A Two-Cohort, Open-Label, Single and Multiple Dose Pharmacokinetic Study of 90 mg and 180 mg Doses of AZD6140 [ticagrelor]in Healthy Chinese Volunteers Living in China
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 24 Apr 2013
Price :
$35
*
At a glance
- Drugs Ticagrelor (Primary)
- Indications Cardiovascular disorders; Embolism and thrombosis
- Focus Pharmacokinetics
- 21 Jan 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 14 Aug 2008 New trial record.